Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
Background: The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. Ho...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
| Saila: | South Asian Journal of Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=2;spage=47;epage=50;aulast=Hingmire |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|